Allergan: latest news - GoINPHARMA
Saturday, 22 September 2018 - 23:54

Allergan

Allergan plans restructuring

Allergan CEO Brent Sanders yesterday said at the Barclay Global Healthcare Conference that the group’s financial performances do reflect the recently-implemented strategy developed together with his team, yet the company’s share price is still too low and does not reflect…

Allergan acquires Elastagen for $95m

Allergan has acquired Elastagen for $A120m ($95m). Elastagen is a spin-off of the University of Sydney focusing on acne scars treatments. Elastagen’s technology is based on human tropoelastin (the precursor of elastin). Elastagen two years ago obtained $13m in funding….

US groups stronger and more competitive thanks to fiscal reform

The JP Morgan Healthcare Conference, which has just ended in San Francisco, has given analysts an opportunity to analyze the different views of big pharma companies’ CEOs . The fiscal reform proposed by the Trump administration has been a widely-debated…

Allergan announces 1,000 staff cuts

Allergan yesterday announced 1,000 job cuts, that is over 5% of its total workforce (18,000 employees). The drastic measure reflects the need to cut costs, as the $1.5bn-worth blockbuster Restasis (eye drops delivering an immunomodulator) has lost its market share…

Allergan acquires Repros Therapeutics

Allergan has announced it has acquired US-based Repros Therapeutics for $26.5m. Repros is a biotech company focusing on the development of drugs to treat infertility and reproductive disorders. The leading product in Repros’ portfolio is probably Enclomiphene, an investigational therapy…

US court declares patent on Allergan’s Restasis invalid

The US District Court for the Eastern District of Texas has ruled that four patents covering Allergan’s Restasis are to be considered invalid. Allergan one month ago transferred the rights to its blockbuster Restasis to the Saint Regis Mohawk Tribe…

Allergan announces 2-billion-worth share repurchase program

Allergan pharmaceutical group’s board today approved a new plan to buy back $2 billion of its shares, and simultaneously announced it plans to partly pay off its debt through a $3.78bn payment expected for 2018. Allergan’s shares rose more than…

NASH: new results from Allergan’s drug

Allergan announced new data from the CENTAUR Phase IIb study which supports the anti-fibrotic efficacy and safety of Cenicriviroc (CVC) for the treatment of liver fibrosis in adults with NASH. The results from a one-year treatment with cenicriviroc were released…

Allergan acquires Keller Medical (plastic surgery)

Allergan announced it acquired Keller Medical, Inc., a medical device producer headquartered in Florida. The acquiree enhances Allergan’s Plastic Surgery and Regenerative Medicine Business. Keller Medical’s main product is Keller Funnel – launched in 2009 – a tool used during…

Investors urge Pfizer to pursue M&A again, shares down 2%

Pressure on Pfizer CEO, Ian Reed, is increasing, indeed Citibank today stated in a report that the US-based pharmaceutical giant will not reach the expected sales volume, unless it performs a significant acquisition. Analysts at the US investment bank downgraded…

Allergan to keep pursuing M&A

During the press conference called by Allergan to announce its 2017 first results, CEO Brenton Saunders announced that the group is planning to carry out bolt-on acquisitions going forward. Saunders specified that Allergan will target companies operating in the same…

Allergan’s first quarter better than expected: company takes pride in Botox

Allergan reported a first quarter exceeding analysts’ and investors’ expectations. Botox’s manufacturer generated revenues of $3.57bn, which represents a 10% increase over Q1 2016. EPS was $3.35, 5 cents over shareholders’ expectations. The outstanding performances were led by sales of…

Allergan-Novartis collaboration for NASH

Allergan announced today it has entered into an agreement with Novartis to conduct a Phase IIb clinical trial assessing Allergan’s cenicriviroc (CVC) and Novartis’ lead FXR agonist for the treatment of NASH. Specifically, the study is aimed at assessing the…

Allergan confirms Botox showed efficacy in treating depression

Allergan announced on Wednesday results from a Phase II, 6-week clinical trial on 258 patients with Major Depressive Disorder treated with Botox. According to the data, the Botox 30U dose showed efficacy in treating depression. Based on the results achieved,…

NASH is the most promising therapeutic area in the pharmaceutical sector

NASH – or non-alcoholic steatohepatitis – is the therapeutic area which many Big Pharma companies are targeting, the most active being Allergan, Gilead and Novartis, which have already invested billions in acquisitions and research programs. NASH is a condition causing…

New takeover for Allergan: acquires Zeltiq for $2.47bn

A new acquisition has been performed by Allergan, which informed today that it has paid $2.47bn in cash for Zeltiq. Zeltiq owns the CoolSculpting System, which allows to cool and then remove fat cells from tissues, which results in tissue…

Allergan/Medicines360, FDA accepts sNDA for Liletta

Allergan and Medicines360, a nonprofit global women’s health organization, announced that FDA has accepted a sNDA (supplemental New Drug Application) for contraceptive device Liletta. The sNDA is aimed at extending the duration of use for the device from three to…

The complex dynamics driving M&A in pharma

According to the consultancy Novasecta, the consolidation trend in the pharma business will continue in 2017, although prices paid by investors are significantly higher (SALESx) than in other sectors. The average price for an acquisition in 2016 was 39 times…

Allergan acquires LifeCell for $2.9bn

Allergan announced it has acquired LifeCell from Acelity for $2.9bn in cash. LifeCell’s manufactures products for plastic surgery and tissue regeneration, used for instance after breast surgery. The acquired company is expected to generate approximately $450m—growing at approximately 5%—75% gross…

NASH, Allergan and Gilead, but Genfit and Intercept too

The NASH (nonalcoholic steatohepatitis) business has the potential to reach as much as $40bn—analysts say—and several companies are targeting it. Among these, Allergan and Gilead likely have the most promising pipelines in the business. However, Genfit and Intercept Pharmaceuticals are…

A tough third quarter for Allergan, shares down 5% (Wall Street)

Allergan’s management announced today its third quarter 2016 results, which did not meet predictions by Wall Street analysts. Allergan generated revenues of £3.62bn in Q3, which represents a 4.4% growth over Q3 2015, yet it is lower than the £3.68bn…

Allergan doesn’t stop and acquires Motus Therapeutics ($200m)

Allergan announced that it has exercised its option to acquire Motus Therapeutics for $200m. Motus is a biopharmaceutical company specialized in peptide therapeutics for the treatment of gastrointestinal disorders, owned by Rhythm Holding Company, LLC. The announcement follows the Phase…

AstraZeneca, agreement with Allergan for inflammatory diseases

AstraZeneca today announced that MedImmune, its R&D arm, has signed a licensing agreement with Allergan for the global rights to MEDI2070, an IL-23 monoclonal antibody currently in a Phase IIb clinical trial. The ongoing trial has been designed to evaluate…